Balyasny Asset Management
NTLA icon

Balyasny Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Balyasny Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-169,286
Closed -$2.17M – 3360
2026
Q1 		$2.17M Buy
+169,286
New +$2.16M ﹤0.01% 1742
2025
Q4 		– Sell
-255,555
Closed -$4.41M – 3407
2025
Q3 		$4.41M Sell
255,555
-1,055,925
-81% -$13M 0.01% 1420
2025
Q2 		$12.3M Sell
1,311,480
-203,605
-13% -$1.67M 0.02% 876
2025
Q1 		$10.8M Sell
1,515,085
-791,209
-34% -$7.99M 0.02% 877
2024
Q4 		$26.9M Buy
2,306,294
+1,556,433
+208% +$24.3M 0.04% 536
2024
Q3 		$15.4M Buy
749,861
+402,378
+116% +$9.28M 0.03% 746
2024
Q2 		$7.78M Buy
347,483
+158,982
+84% +$3.79M 0.01% 990
2024
Q1 		$5.19M Buy
+188,501
New +$5.24M 0.01% 1205
2023
Q1 		– Sell
-762
Closed -$26.6K – 2994
2022
Q4 		$26.6K Sell
762
-38,927
-98% -$1.85M ﹤0.01% 2447
2022
Q3 		$2.22M Buy
+39,689
New +$2.46M 0.01% 1437
2021
Q2 		– Sell
-38,720
Closed -$3.11M – 2231
2021
Q1 		$3.11M Sell
38,720
-44,473
-53% -$2.99M 0.02% 872
2020
Q4 		$4.53M Buy
+83,193
New +$3.02M 0.03% 679
2019
Q3 		– Sell
-57,321
Closed -$938K – 1452
2019
Q2 		$938K Buy
57,321
+11,675
+26% +$184K 0.01% 1094
2019
Q1 		$780K Sell
45,646
-1,265
-3% -$18.9K 0.01% 1086
2018
Q4 		$640K Buy
+46,911
New +$872K ﹤0.01% 1032

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Balyasny Asset Management's NTLA Position: Q2 2026 in Review

Balyasny Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 169,286 shares — an estimated $2.17M sold.

Balyasny Asset Management first reported a position in NTLA in Q4 2018 and held it in 15 quarters. The position peaked at $26.9M in Q4 2024. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Balyasny Asset Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 169,286 Intellia Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Balyasny Asset Management first reported a position in Intellia Therapeutics in Q4 2018 and held it in 15 quarters.
  • Balyasny Asset Management's Intellia Therapeutics position peaked at $26.9M in Q4 2024.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.